|
|
Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging MarketPublished by: Decision Resources Published: Mar. 26, 2007 - 21 Pages The price of this report has been reduced due to its age. The original price was $2,025 for PDF.Table of Contents
AbstractA poorly understood, complex disease that involves a number of neurotransmitters, bipolar disorder presents several challenges for pharmaceutical companies seeking to develop new treatments. While lithium and several antiepileptic and antipsychotic agents are currently used to treat either manic or mixed episodes of BPD, only Eli Lilly's Symbyax and AstraZeneca's Seroquel have received FDA approval for treatment of bipolar depression. The numerous unmet therapeutic needs resulting from the incomplete understanding of BPD create significant opportunities within the competitive BPD market.Get the Answers You Need to Shape Your Strategy Bipolar disorder represents a market with significant opportunity, but few drug companies are actively developing new agents. What obstacles are currently deterring companies from entering the BPD market? What challenges need to be addressed, and what therapeutic needs remain unmet? The treatment of depression associated with BPD has not been as extensively studied as the treatment of either unipolar depression or bipolar mania. What strategies does treatment of bipolar depression rely upon? Which classes of antidepressants appear to be the most effective for treating bipolar depression? Several agents have received specifi c approval for treating BPD; other agents are commonly used off-label. Which agents are most frequently used as off-label treatments for BPD? What competitive advantages, if any, does FDA approval provide? Which companies are specifi cally pursuing FDA approval for their BPD agents? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||